REAL SCIENCE. REAL POSSIBILITIES.A naturally occurring signalling peptide with wide-ranging research into breathing, circulation, inflammation and gut health.
VIP sits in nerves, immune signalling, airways, blood vessels and the gut. That breadth makes route, concentration and disease context especially important.
These cards show what VIP is best known for and where the interest comes from. When you want the detail, open Research for the studies or Evidence for a quick view of how strong the support is.
The main reasons this compound attracts attention. The Research and Evidence sections give you the deeper scientific picture.
VIP can relax pulmonary vascular smooth muscle.
Twenty patients inhaled 100 micrograms during right-heart catheterisation; the effect was selective but modest and short-lived.
Aviptadil is explored around alveolar cells, surfactant and inflammatory lung injury.
The rationale reached large trials, but intravenous treatment did not improve 90-day outcomes in TESICO.
VIP can influence immune signalling, creating interest around whether it might help regulate excessive inflammation in particular disease settings.
Context-dependent signalling does not establish general ‘immune support’ or a safe injectable protocol.
VIP is an enteric neurotransmitter involved in secretion, motility and smooth-muscle relaxation.
Endogenous physiology does not show that administered VIP improves digestion, dysbiosis or ‘gut healing’.
VIP biology spans lung, vessels, nerves, immune cells and gut. Human translation therefore has to be read route by route: inhaled acute physiology is not intravenous outcome efficacy or subcutaneous wellness use.
Pulmonary, vascular, neural and intestinal signalling
→Modest temporary pulmonary vasodilation
→Large TESICO programme stopped for futility
→No general subcutaneous protocol or indication
VIP sits in nerves, immune signalling, airways, blood vessels and the gut. That breadth makes route, concentration and disease context especially important.
Twenty patients inhaled 100 micrograms during right-heart catheterisation; the effect was selective but modest and short-lived.
The rationale reached large trials, but intravenous treatment did not improve 90-day outcomes in TESICO.
Context-dependent signalling does not establish general ‘immune support’ or a safe injectable protocol.
Endogenous physiology does not show that administered VIP improves digestion, dysbiosis or ‘gut healing’.
20 adults with chronic pulmonary hypertension
461 treated adults with COVID-19 hypoxaemic respiratory failure
132 hospitalized adults at high risk of ARDS
Aviptadil has been administered in pulmonary hypertension and respiratory-failure studies.
Small physiological signals have not become established benefit; TESICO was negative.
Trials provide route-specific short-term data, not repeated self-use safety.
Substantial receptor, vascular, pulmonary, intestinal and immune research supports plausibility.
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Inhaled and intravenous pulmonary programmes
Large critical-COVID trial was negative
No chronic pulmonary or wellness schedule
An active biological pathway can justify a trial. It cannot make an untested formulation, indication or long-term schedule evidence-based.
Breathing, post-viral recovery, immune balance and gut–brain goals—mapped against route-specific pulmonary studies and a negative large trial.
Pulmonary research · route matters · efficacy boundaryVIP is explored for breathing, post-viral recovery, immune balance and gut–brain symptoms. It has genuine human pulmonary research, but positive narratives must be read beside modest acute physiology and a negative large intravenous trial.
Experiences can reveal recurring goals, perceived changes and practical questions that formal studies may not yet address. They can suggest what deserves investigation, but cannot isolate the effect of one compound from rehabilitation, time or other changes.
Human and preclinical research helps test whether an idea is biologically plausible, whether it appears in people and how confidently the result can be separated from chance, bias or other parts of recovery.
People are attracted to the vasodilator and pulmonary story.
A 20-person inhalation study found modest, temporary vasodilation.
VIP receptors occur across pulmonary vascular and airway tissues.
A credible acute signal that did not establish chronic treatment.
Interest expanded during COVID-19 and is extended to prolonged symptoms.
TESICO found no clinical or mortality improvement with IV aviptadil.
Alveolar and inflammatory mechanisms supported the trial rationale.
The strongest controlled evidence is negative for that setting.
VIP is framed as calming excessive inflammation.
No broad immune-support indication or consumer trial exists.
Effects on cytokines and immune cells are context-dependent.
Mechanistic depth does not create a general immune therapy.
Users connect enteric roles with digestion, dysautonomia or brain fog.
Direct treatment evidence for these clusters is insufficient.
VIP participates in secretion, motility and neural signalling.
Established physiology with unproven administered benefit.
Community reports can surface patterns worth exploring. Controlled human research is what tests whether those patterns are reliable, clinically meaningful and attributable toVIP, while the available studies show how far that question has already been answered.
Compare published study protocols with the patterns people discuss in the community. The two are intentionally kept separate so an anecdotal routine is never mistaken for clinical guidance.
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
VIP/aviptadil research doses are route- and disease-specific; no general subcutaneous dose or wellness cycle has been validated.
The clearest inhaled physiology study used a single 100 microgram dose under catheterisation monitoring.
TESICO used three daily 12-hour IV infusions with weight-based escalation; it was an intensive-care trial, not a titration template.
No evidence-based maintenance schedule exists for lung health, immune support, gut symptoms or recovery.
See the thinking behind community-named stacks, the different role each component is proposed to play, and how much of that idea has actually been tested as a combination.
Aviptadil research treatment + Respiratory care
VIP + LL-37 or another immune-active peptide
VIP + BPC-157
Trials used monitored hospital or catheterisation settings.
Research context only; efficacy depends on disease and route.Discussed as complementary immune signalling.
No controlled human combination evidence establishes benefit or safe dosing.Community interest combines gut-neural signalling with tissue protection.
No human study validates synergy, route or interaction safety.The summary above reflects the human or preclinical evidence currently represented on this profile.
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Short endogenous half-life does not make repeated dosing safe, and retail subcutaneous products are not equivalent to clinical formulations.
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
VIP / aviptadil is presented as an experimental compound. Product identity, quality and supply sit outside an approved prescribing pathway.
MHRA products database ↗A published experiment is not approval for safety and efficacy.
Drugs@FDA ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.
